Federated Investors Inc. PA decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 29.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 496,219 shares of the company’s stock after selling 203,132 shares during the period. Federated Investors Inc. PA’s holdings in Johnson & Johnson were worth $68,562,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Rehmann Capital Advisory Group grew its holdings in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Rehmann Capital Advisory Group now owns 35,591 shares of the company’s stock worth $4,918,000 after acquiring an additional 256 shares during the period. PDS Planning Inc grew its holdings in shares of Johnson & Johnson by 10.8% during the 3rd quarter. PDS Planning Inc now owns 3,673 shares of the company’s stock worth $507,000 after acquiring an additional 357 shares during the period. Trust Department MB Financial Bank N A grew its stake in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Trust Department MB Financial Bank N A now owns 98,938 shares of the company’s stock worth $13,670,000 after buying an additional 363 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Johnson & Johnson by 3.0% in the 3rd quarter. Global Retirement Partners LLC now owns 12,394 shares of the company’s stock worth $1,712,000 after buying an additional 365 shares during the last quarter. Finally, Canal Capital Management LLC grew its stake in shares of Johnson & Johnson by 2.3% in the 3rd quarter. Canal Capital Management LLC now owns 16,077 shares of the company’s stock worth $2,221,000 after buying an additional 365 shares during the last quarter. 66.56% of the stock is owned by institutional investors and hedge funds.
Several research firms recently weighed in on JNJ. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a research note on Wednesday, November 28th. Morgan Stanley cut their price target on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Barclays restated an “equal weight” rating and issued a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Finally, Wells Fargo & Co restated an “outperform” rating and issued a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $142.81.
JNJ stock opened at $137.17 on Tuesday. The company has a market capitalization of $369.17 billion, a P/E ratio of 16.77, a price-to-earnings-growth ratio of 2.13 and a beta of 0.68. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 22nd. The company reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.02. The business had revenue of $20.39 billion for the quarter, compared to analysts’ expectations of $20.27 billion. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.74 EPS. As a group, analysts forecast that Johnson & Johnson will post 8.57 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th were given a $0.90 dividend. The ex-dividend date of this dividend was Monday, February 25th. This represents a $3.60 annualized dividend and a yield of 2.62%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 44.01%.
Johnson & Johnson declared that its board has initiated a stock repurchase plan on Monday, December 17th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 1.5% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
COPYRIGHT VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2019/03/19/johnson-johnson-jnj-holdings-reduced-by-federated-investors-inc-pa.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: How to invest in blue-chip stocks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.